A retrospective study on veterans with both diabetes and COPD revealed that the risk of COPD exacerbations in patients receiving PPARγ agonists was significantly lower than that in patients receiving other diabetes medications (129). Here, PPARG is linked to chronic obstructive pulmonary disease.